Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	163.19
Equity-to-Asset	0.84
Debt-to-Equity	0.01
Debt-to-EBITDA	0.02
Interest Coverage	10.95
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	17.8	Distress Grey Safe
Beneish M-Score	-2.33	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	32.8
	3-Year EBITDA Growth Rate	52.7
	3-Year EPS without NRI Growth Rate	21.4
	3-Year FCF Growth Rate	37.9
	3-Year Book Growth Rate	30.7
	Future 3-5Y Total Revenue Growth Rate	12.87

Momentum Rank

4/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	47.71
	9-Day RSI	53.48
	14-Day RSI	53.65
	6-1 Month Momentum %	-11.63
	12-1 Month Momentum %	-29.74

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	6.86
	Quick Ratio	6.43
	Cash Ratio	5.94
	Days Inventory	408.56
	Days Sales Outstanding	66.73
	Days Payable	208.45

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	0.33
	Dividend Payout Ratio	0.09
	3-Year Dividend Growth Rate	17
	Forward Dividend Yield %	0.33
	5-Year Yield-on-Cost %	0.33
	Shareholder Yield %	0.35

Profitability Rank

9/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	90.27
	Operating Margin %	53.2
	Net Margin %	37.12
	FCF Margin %	44.66
	ROE %	18.75
	ROA %	15.99
	ROIC %	107.56
	ROC (Joel Greenblatt) %	766.2
	ROCE %	30.26
	Years of Profitability over Past 10-Year	7

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	26.35
	Forward PE Ratio	18.45
	PE Ratio without NRI	26.35
	Shiller PE Ratio	65.7
	Price-to-Owner-Earnings	25.21
	PEG Ratio	0.84
	PS Ratio	9.88
	PB Ratio	4.24
	Price-to-Tangible-Book	4.21
	Price-to-Free-Cash-Flow	21.85
	Price-to-Operating-Cash-Flow	18.78
	EV-to-EBIT	11.8
	EV-to-EBITDA	11.58
	EV-to-Revenue	7.22
	EV-to-FCF	16.06
	Price-to-Projected-FCF	1.75
	Price-to-Median-PS-Value	0.26
	Price-to-Peter-Lynch-Fair-Value	1.01
	Price-to-Graham-Number	2.21
	Price-to-Net-Current-Asset-Value	4.45
	Price-to-Net-Cash	5.3
	Earnings Yield (Greenblatt) %	8.48
	FCF Yield %	4.79
	Forward Rate of Return (Yacktman) %	22.96

Financials

Annual Quarterly TTM

FRA:UR9's 30-Y Financials

AAPL

Income Statement Breakdown

Annual Quarterly

No Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

No Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

No Enough Data

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

No Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015

Clinuvel Pharmaceuticals Ltd Executives

Details

GF Value: €25.76

FRA:UR9

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with UR9. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	50.132
	EPS (TTM) (€)	0.354
	Beta	1.45
	Volatility %	35.64
	14-Day RSI	53.65
	14-Day ATR (€)	0.220827
	20-Day SMA (€)	9.02165
	12-1 Month Momentum %	-29.74
	52-Week Range (€)	7.902 - 12.795
	Shares Outstanding (Mil)	50.13

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	7
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Clinuvel Pharmaceuticals Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Clinuvel Pharmaceuticals Ltd Stock Events

Financials Calendars

	Event	Date	Price(€)
No Event Data

Clinuvel Pharmaceuticals Ltd Frequently Asked Questions

What is Clinuvel Pharmaceuticals Ltd(FRA:UR9)'s stock price today?

The current price of FRA:UR9 is €9.18. The 52 week high of FRA:UR9 is €12.80 and 52 week low is €7.90.

When is next earnings date of Clinuvel Pharmaceuticals Ltd(FRA:UR9)?

The next earnings date of Clinuvel Pharmaceuticals Ltd(FRA:UR9) is .

Does Clinuvel Pharmaceuticals Ltd(FRA:UR9) pay dividends? If so, how much?

The Dividend Yield % of Clinuvel Pharmaceuticals Ltd(FRA:UR9) is 0.33% (As of Today), Highest Dividend Payout Ratio of Clinuvel Pharmaceuticals Ltd(FRA:UR9) was 0.09. The lowest was 0.05. And the median was 0.06. The Forward Dividend Yield % of Clinuvel Pharmaceuticals Ltd(FRA:UR9) is 0.33%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
No Press Release

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Data is updated daily.